May 27, 2025 Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma The ASCO Post
Omar Nadeem, MD discusses results of the Phase II d-PRISM study Daratumumab in high-rish MGUS and low-risk smoldering myeloma View All Authors Show Fewer Dana-Farber December 22, 2025 Please enable JavaScript or upgrade to a modern browser to view this video. Daratumumab in high-rish MGUS and low-risk smoldering myeloma
